Ajanta Pharma Limited issued a formal clarification on February 10, 2026, regarding a news report suggesting the company might raise Rs 2,000 crore to acquire Restaurant Brands Asia. The company explicitly stated that Ajanta Pharma and its management are not involved in the reported transaction. The article mistakenly linked the drugmaker to the acquisition, which is reportedly being managed by a section of the promoter group independently.
Response to Media Speculation
Ajanta Pharma Limited released a formal clarification on February 10, 2026, addressing a news article published in The Economic Times that suggested the company was planning a major diversification move. The article, dated February 10, 2026, claimed that Ajanta “may raise Rs 2,000 crore to buy Restaurant Brands Asia.”
Distinction Between Company and Promoter Group Activity
The company pointed out that the published report contained an incorrect and inadvertent reference, stating that the transaction would mark the drugmaker’s diversification into the quick service restaurant sector. Ajanta Pharma clearly stated that it and its management are not parties to, nor involved in, any such transaction.
It was further clarified that a separate section of the promoter group, which manages Lenexis Foodworks Pvt. Ltd., is independently pursuing the acquisition of Restaurant Brands Asia. Consequently, the reference to Ajanta Pharma Limited in the said article is deemed factually incorrect, and the company formally denies the rumours and speculation circulating in this regard.
Source: BSE
